



I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. ER509325303US, in an envelope addressed to: US Non Fee Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: August 19, 2004

Signature: *Staci Harris*

(Staci Harris)

Docket No.: HO-P02681US1  
(PATENT)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of:  
Orla M. Conneely et al.

Application No.: 09/058,589

Art Unit: 1617

Filed: April 10, 1998

Examiner: S. Wang

For: LACTOFERRIN AS REGULATOR OF  
ALLERGEN-INDUCED TUMOR NECROSIS  
FACTOR-ALPHA PRODUCTION AND  
THERAPEUTIC APPLICATIONS

**AMENDMENT & RESPONSE**

MS NON/FEE AMENDMENT  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

**INTRODUCTORY COMMENTS**

In response to the Advisory Action dated May 20, 2004, please amend the above-identified U.S. patent application as follows:

**Interview Summary** begins on page 2 of this paper.

**Amendments to the Claims** are reflected on page 3.

**Remarks/Arguments** begin on page 5 of this paper.

**INTERVIEW SUMMARY**

On June 3, 2004, the representative for the Applicants, Melissa Acosta conducted a telephonic interview with Examiner Wang. The claims and the prior art, Morinaga Milk Inc., were discussed. During the interview, Applicants discussed claim amendments, for example placement of the term “consisting essentially of” as it relates to lactoferrin.